Telomir identifies Telomir-Ag2, stabilized Silver(II) complex with broad-spectrum antibacterial activity

Telomir Pharmaceuticals, Inc.

Telomir-Ag2 is a novel drug candidate from the proprietary Telomir-1 platform, stabilized Silver(II).
Minimum Inhibitory Concentration (MIC) study shows broad-spectrum activity against Gram-positive and Gram-negative strains.
Active against methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA).
Telomir-Ag2 exhibited greater antibacterial activity than the earlier Silver(I)-based Telomir-Ag1 formulation.
Company plans formulation development and regulatory pathways targeting drug-resistant infections in burn wounds and post-surgical settings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.